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Teaser The structural requirements for novel highly potent and selective agonists and
antagonists of prostaglandin EP1 to EP4 receptors and their therapeutic potential are
presented in this original review.
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Prostaglandin E2 is a potent endogenous molecule that binds to four
different G-protein-coupled receptors: EP1–4. Each of these receptors is a
valuable drug target, with distinct tissue localisation and signalling
pathways. We review the structural features of EP modulators required for
subtype-selective activity, as well as the structural requirements for
improved pharmacokinetic parameters. Novel EP receptor subtype
selective agonists and antagonists appear to be valuable drug candidates in
the therapy of many pathophysiological states, including ulcerative
colitis, glaucoma, bone healing, B cell lymphoma, neurological diseases,
among others, which have been studied in vitro, in vivo and in early phase
clinical trials.
Introduction
Prostaglandin E2 (PGE2) is the most widely produced prostanoid in the human body. It signals via
four specific G-protein-coupled receptors: EP1–4, responsible for distinct biological outcomes [1].
The engineering of mice deficient in each respective EP receptor enabled the elucidation of PGE2-
mediated processes including inflammation, bone healing, regulation of gastrointestinal mucosa,
embryo implantation, induction of labour and vasodilatation [2–4]. The understanding of the
role of PGE2 in human physiological and pathophysiological conditions has also been facilitated
by the development of highly selective agonists and antagonists of these receptors [2–5].
Manipulation of PGE2-mediated processes would be of great importance, in particular if the
enormous therapeutic potential of selective EP receptor modulation could be exploited.
PGE2 is a very unstable molecule with an extremely short half-life. It rapidly undergoes
terminal- and beta-oxidation in vivo and is of limited clinical use. PGE2 is approved for human
use to induce childbirth and as a vasodilator in severe ischemia or pulmonary hypertension. Its
other therapeutic potentialities are not exploited owing to its systemic effects, including side-
effects such as lethargy, headache, diarrhoea and flushing [2,3]. To overcome these unwanted
effects of PGE2, novel potent and specific agonists and antagonists of distinct EP receptors have
been developed, especially in the past decade, exploring a vast diversity of scaffolds. The timeline
of pivotal discoveries concerning EP receptors and their modulators is depicted in Fig. 1. We
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FIGURE 1
Chronological overview of key discoveries in the field of prostaglandin E2 (PGE2) receptor modulators [4,5,14,16,31,32,67–69,78–80,85–103]. Abbreviations: DP,
prostaglandin D2 receptor; EP, prostaglsndin E2 receptor; FP, prostaglandin F2a receptor; IP, prostacyclin receptor; TP, thromboxane A2 receptor.review novel potent and selective ligands of EP receptors reported
in the past decade with the emphasis on the diversity of reported
scaffolds, followed by the reported therapeutic indications and an
overview of relevant clinical trials.
PGE2 receptor subtypes
PGE2 is a potent endogenous molecule, synthesised by constitu-
tive (COX-1) and inducible (COX-2) cyclooxygenases and the
cytosolic (cPGES-1) and microsomal (mPGES-1 and mPGES-2)
prostaglandin E synthases (Fig. 2) [1]. It binds to prostaglandin
receptors EP1–4. All four EP receptor subtypes respond to PGE2,
despite their relatively low amino acid sequence similarities. The
percentages of sequence similarities of EP1 to EP2, EP3 and EP4 are
30%, 33% and 28%, respectively. The EP2 and EP4 receptors,
which have similar signalling pathways via activation of adenylate
cyclase, share only 31% homology [4,6].
Each EP receptor subtype is specifically distributed in the hu-
man body; EP1: myometrium, pulmonary veins, colon, skin, mast
cells; EP2: leukocytes, smooth muscle, central nervous system
(CNS), reproductive system, bones; EP3: CNS, cardiovascular sys-
tem, reproductive system, kidney, urinary bladder; EP4: leuko-
cytes, smooth muscle, cardiovascular system and bones [4,5].
Among the four PGE2 receptors, EP3 and EP4 are the most widely
expressed. By contrast, the distribution of the EP1 receptor is
restricted to a few organs in humans whereas it is more widely
distributed in rodents [5]. All EP receptor subtypes are present on
the plasma membrane; EP3 and EP4 are also expressed on the cell
nuclei membranes [7]. In addition to the differences in tissue
localisation, EP receptor subtypes also differ in their expression
regulation mechanisms and signal transduction pathways [4].58 www.drugdiscoverytoday.comSignal transduction pathways
The PGE2 receptors EP1–4 as well as other prostanoid receptors DP,
FP, IP and TP are G-protein-coupled receptors [5]. The EP receptors
are composed of seven transmembrane segments with each recep-
tor subtype being coupled to a different subunit of heterotrimeric
G proteins. Ligand binding to different EP receptors leads to the
activation of distinct downstream signalling pathways (Fig. 2) [6].
The EP1 receptor is somewhat unique among the PGE2 recep-
tors in that it is coupled to Gq protein and belongs to a ‘contractile’
receptor group. The binding of PGE2 to the EP1 receptor activates
phospholipase C (PLC), which mediates the activation of protein
kinase C (PKC), in turn resulting in increased phosphatidylinositol
hydrolysis and the elevation of the intracellular calcium concen-
tration [8]. The activation of the EP3 receptor results in the
inhibition of adenylate cyclase via Gi protein, which lowers cyclic
adenosine monophosphate (cAMP) levels; EP3 has therefore been
classified as an ‘inhibitory’ receptor. Three isoforms of mouse EP3
and eight of human EP3 have been identified [9,10]. The EP2 and
EP4 receptors activate adenylate cyclase and increase cAMP levels
by coupling to Gs proteins and have been classified as ‘relaxant’
receptors. Interestingly, in many processes EP2 and EP4 play
different parts. Obviously, EP receptors do not couple exclusively
to the pathways described, but often to more than one G protein
and the underlying signal transduction pathway [11,12] (Fig. 2).
For instance, EP4 receptor signals via Gi, phosphatidylinositol 3-
kinase (PI3K), b-arrestin or b-catenin [13,14]. The co-localisation
of the EP4 receptor with an EP4-receptor-associated protein
(EPRAP) has revealed an interaction with the transcription factor
nuclear factor (NF)-kB that causes a decrease in the secretion of
proinflammatory cytokines [6,15,16].
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FIGURE 2
Prostaglandin E2 (PGE2) signalling. Overview of the arachidonic acid cascade, PGE2 synthesis and its binding affinities to EP receptor subtypes involving their
major signalling pathways. PGE2 is one of the prostanoids involved in the arachidonic acid cascade. The latter is initiated by various physiological and
pathophysiological stimuli, which, in turn, result in the hydrolysis of the ester linkage that binds arachidonic acid to glycerol in phospholipids by phospholipase A2.
Next, arachidonic acid undergoes oxidation to eicosanoids, a process catalysed predominantly by two groups of enzymes, cyclooxygenases (COX) and
lipoxygenases (LOX), which produce prostanoids and leukotrienes, respectively. COX enzymes catalyse the formation of prostaglandin PGH2 in the sequential step
of PG synthesis involving the formation of the intermediate PGG2. PGH2 then serves as a key substrate for the conversion to prostaglandins PGD2, PGE2, PGF2,
PGI2 and thromboxane A2 by cell-specific synthases or isomerases. These potent prostanoid signalling molecules exert their effects through autocrine and
paracrine stimulation of eight specific G-protein-coupled receptors (GPCRs), designated DP, EP1 to EP4, FP, IP and TP. PGE2 binds to the prostaglandin receptors
EP1–4. Dissociation constants (Kd) of PGE2 are as follows: EP1: 25 nM (human); 20 nM (mouse); EP2: 13 nM (human); 12 nM (mouse); EP3: 0.3 nM (human); 0.9 nM
(mouse); EP4: 0.6 nM (human); 1.9 nM (mouse). Major signalling pathways involve activation of adenylate cyclase (EP2 and EP4) and consequent increase in cAMP,
inhibition of adenylate cyclase (EP3), decrease in cAMP and activation of phospholipase C, resulting in the increase in intracellular calcium (EP1). Furthermore,
binding of PGE2 to EP4 receptor results in activation of alternative pathways. Abbreviations: COX, cyclooxygenase; LOX, lipoxigenase; PGG2, prostaglandin G2;
PGH2, prostaglandin H2; PGES, prostaglandin E synthases; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF2a, prostaglandin F2a; PGI2, prostaglandin I2;
EPRAP, EP4 receptor-associated protein; IP3, inositol trisphosphate; cAMP, cyclic adenosine monophosphate. This figure was produced using Servier Medical Art.
Adapted, from [6,11,12,17,18,104].
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tor subtypes are dependent on the concentration and the confor-
mation of the cognate ligand of the subtype [6]. PGE2 binding
affinities for each EP receptor subtype were determined for human
and mouse prostanoid receptors [17,18] (Fig. 2). Equilibrium dis-
sociation constants (Kd) of the radiolabelled ligand PGE2 were
determined for each receptor subtype. PGE2 retains agonist activity
in the nanomolar range at all four EP receptor subtypes, although
they only share 20–30% of their structural homology. In brief, PGE2
has been shown to bind to EP3 and EP4 receptors with higher
affinities when compared with the affinities towards EP1 and EP2
receptors, with Kd values ranging from 0.3 to 25 nM [17,18] (Fig. 2).In summary, the interactions between PGE2 and the EP recep-
tors depend on tissue or cell type, specific receptor expression and
differences in binding affinities, leading to unique EP receptor
activation. Hence, PGE2 has the ability to cause diverse effects in
many different tissues, thus playing distinct parts in different
physiological and pathophysiological conditions.
EP receptor modulators
PGE2 is composed of a cyclopentanone core with appended a- and
v-lipophilic side-chains at position-8 and -12. The a-chain incor-
porates a 5,6-double-bond element and is terminated by a carbox-
ylic moiety. The v-chain ends with a methyl group and it alsowww.drugdiscoverytoday.com 59
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two hydroxyl groups, one attached to position-11 of the cyclo-
pentanone scaffold and the other to position-15 of the v-chain. It
is worth noting that the natural stereochemistry of PGE2 corre-
sponds to the 8-(R), 12-(R), 15-(S) configuration. The prostaglandin
numbering and all structural features of PGE2 (1) are depicted in
detail in Fig. 3a.
Owing to the pleiotropic effects of PGE2, mediated by EP1–4, EP
receptor subtype specific ligands constitute a hot topic in medici-
nal chemistry. The well characterised structure of prostanoid
receptors enables a systematic analysis of the binding character-
istics of a therapeutic and the determination of the selectivity for
those receptors. Several recently patented ligands and general
structures have been reviewed [19]. Because very little bioactivity
and biologically oriented data are included in the patent literature,
we focused our attention predominantly on published papers
containing complete affinity and selectivity data. The affinity data
of presented ligands of EP receptors (expressed as Ki or pKi) and
their potency and activity data (expressed as EC50, IC50 or Kb
values) are listed in Table S1 (see supplementary material online).
We discuss these ligands in terms of their oral bioavailability and
CNS penetration – their ability to cross the blood–brain barrier
(pharmacokinetic data of selected ligands are listed in Table S2, see
supplementary material online). This ability determines whether,
and to what extent, these ligands will mediate central versus
peripheral EP-mediated activity.
EP1 receptor modulators
Despite the well-established key pharmacophores required for EP1
receptor agonist activity of prostaglandin derivatives [20], only
one EP1-selective agonist: ONO-D1-004 (2) (Ki = 150 nM), has
been identified to date (Fig. 3b) [21]. By contrast, several dual
EP1/EP3 agonists with nanomolar affinities to both receptors have
been reported, including 17-phenyltrinor PGE2 and carbacyclin,
to name but two [18,20]. Most marketed prostanoid agonists,
although fairly potent, exhibit poor selectivity.
The majority of EP1 ligands were designed as antagonists of this
receptor to be used as potential treatment for hyperalgesia (shown
in Fig. 3c). Surprisingly, none of these ligands are structurally similar
to PGE2. The tricyclic EP1 antagonist SC51322 (3) displays a low
nanomolar affinity for the EP1 receptor (Ki = 13.8 nM) [17]. Com-
pound 4 belongs the biphenylene dibenzazocinone class of com-
pounds, and is proven to be a selective and potent EP1 receptor
antagonist (Ki = 17 nM) and structurally resembling SC51322 [22].
Ono Pharmaceuticals disclosed a set of N-phenylheteroarylsulfona-
mides, exemplified by compound 5, which have inhibitory
activities in the low nanomolar range and high selectivity for the
EP1 receptor [23]. Unfortunately, these compounds contain a high-
ly lipophilic arylsulfonyl moiety that precluded them from entering
clinical studies. Compound 6, developed by Astellas Pharma, was
based on a scaffold related to compound 5 and was also found to
exhibit subnanomolar affinity with a Ki value of 0.33 nM [19].
Compound 7, which belongs to a structurally different class of
substituted indazoles developed by Asahi Kasei Pharma, has an
IC50 value of <20 nM [19]. Initial research at GlaxoSmithKline
(GSK) has demonstrated that GW-848687X (8), which incorpo-
rates a 1,2-biaryl-cyclopentene pharmacophore, possesses nano-
molar affinity for the EP1 receptor (pKi = 8.6) while also displaying60 www.drugdiscoverytoday.comhigh selectivity and, most importantly, in vivo efficacy in inflam-
matory pain preclinical models, owing to good CNS penetration
[24]. Because GW-848687X (8) might undergo oxidation at the
allylic position of the cyclopentene ring under in vivo conditions, a
potential backup compound, GSK-345931A (9), has been devel-
oped that carries an ortho-substituted aryl moiety in place of the
cyclopentene ring. Although it possesses a slightly lower binding
affinity (pKi = 7.8), compound 9 displays improved pharmacoki-
netic parameters, including good metabolic stability, as well as
good CNS penetration and, above all, excellent in vivo efficacy [25].
Further efforts led to the discovery of a methylene-linked picolinic
acid derivative GSK-269984A (10) that overcame the major devel-
opment issues encountered with previous compounds; conse-
quently, it was selected as a development candidate for
treatment of inflammatory pain [25]. In addition, the researchers
at GSK identified the first nonacidic benzofuran-based EP1 antag-
onist (11) (pKi = 8.0) with good CNS penetration and promising
efficacy [26]. Several other EP1 antagonists exhibiting affinity in
the nanomolar range have been described [19]; however, they
have not been included in this review owing to a lack of selectivity
data.
EP2 receptor modulators
Increased EP2 transduced signalling is implicated in seizures and
epilepsy, whereas its decrease is implicated in glaucoma, bone
healing and pulmonary fibrosis. Thus, agonists and antagonists are
of potential clinical use. However, in contrast to the EP1 mod-
ulators, the field of EP2 modulators has been focused on the
development of selective agonists, whereas little effort has been
made to discover selective antagonists. As a result, three classes of
EP2 receptor agonists have been reported to date, and EP2-selective
antagonists have emerged only recently (shown in Fig. 3d and e,
respectively).
The first class of agonists comprises ligands that structurally
resemble the endogenous ligand PGE2 but incorporate major
modifications in the v-lipophilic chain that contribute to en-
hanced potency and selectivity. The free acid metabolite of buta-
prost (12) was one of the first selective EP2 agonists reported [27];
however, its clinical usefulness is limited because of its chemical
instability and weak potency relative to PGE2. More specifically,
the hydroxy-cyclopentanone ring of butaprost is prone to dehy-
dration, which renders the compound inactive. Nevertheless, its
uniquely designed v-chain provided a template for the develop-
ment of several more-potent and more-selective EP2 agonists of
the prostanoid type, 16-hydroxy-17,12-trimethylene PGF deriva-
tives. By virtue of a minor chemical modification, namely the
introduction of a 9b-chloro group in place of the C9-carbonyl
moiety, compounds 13 (EC50 = 2.8 nM; Ki = 2.2 nM) and 14
(EC50 = 1.8 nM; Ki = 1.7 nM) have been obtained. These com-
pounds are much more resistant to degradation and have a prom-
ising selectivity and agonist activity profile [27,28]. Compound 13
has been additionally stabilised as a lysine salt. The second class of
agonists is a series of pyridyl-sulfonamide derivatives developed by
Pfizer, the most potent being taprenepag isopropyl [also designat-
ed PF-04217329 (15)], the prodrug of active acid metabolite CP-
544326 (16) (Ki = 10 nM; EC50 = 2.8 nM) [29].
Compound 17 belongs to the third class, a set of pyridylami-
noacetic acids disclosed by Ube Industries. It is the most potent
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FIGURE 3
Key structural features of prostaglandin E2 (PGE2) and subtype-selective modulators of EP1 and EP2 receptor. (a) Key structural features of PGE2. (b) Selective
agonists of EP1 receptor. (c) Selective antagonists of EP1 receptor. (d) Selective agonists of EP2 receptor. (e) Selective antagonists of EP2 receptor.
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also in terms of binding affinity (Ki = 2.8 nM) [30]. It should be
noted that the report lacked data regarding the selectivity of the
compound. Finally, TG3-95-1 (18), although only weakly active
(EC50 = 7.8 mM), is worth mentioning because it represents the
only identified EP2-selective class of allosteric potentiators [29].
Only a few selective EP2 antagonists have been reported
(Fig. 3e). PF-04418948 (19), an azetidine-3-carboxylic acid deriva-
tive, was the first selective EP2 antagonist, it has an IC50 of 16 nM
(Kb = 1.8 nM), exhibiting >10 000-fold increase in selectivity for
the EP2 receptor relative to other prostanoid receptors [29,31]. In
addition, cinnamic amides have been identified as a new class of
selective EP2 antagonists. Two representatives of this class are
shown in Fig. 3e: compound TG4-155 (20) and compound TG8-
4 (21), with Kb values of 2.4 nM and 11.4 nM, respectively. Despite
the structural similarity between these two compounds, the intro-
duction of two pendant hydroxyethyl ether moieties in the struc-
ture of TG8-4 brought about a significantly enhanced aqueous
solubility.
TG8-4 also displays improved EP2 selectivity over prostanoid
receptors relative to that of TG4-155. Recently, another chemical
class of carbamothioacrylamide antagonists has been discovered
by the Ganesh group, as exemplified by TG6-129 (22), which
displays potency at nanomolar concentrations (Kb = 8.8 nM)
and also possesses high selectivity [32]. In contrast to TG4-155
and TG8-4, TG6-129 cannot cross the blood–brain barrier, with the
consequence that it might only be useful as a probe for peripheral
disease models. Other EP2 agonists and antagonists of potential
importance reported in the patent literature will not be discussed
here because they have been highlighted in recent reviews [19,29].
EP3 receptor modulators
In the field of EP3 receptor modulators, the main focus has been on
the discovery of novel selective antagonists of the EP3 receptor
(examples are shown in Fig. 4a) as potential antithrombotics. Most
selective antagonists of the EP3 receptor consist of an acidic proton
and a lipophilic tail. Initially, Merck reported a series of biaryl-ene-
acylsulfonamides exemplified by compound L798,106 (23) with a
Ki value of 0.3 nM [33]. Afterwards, two additional classes of
selective EP3 antagonists were developed based on this series,
differing in the nature of the acidic moiety. It is worth noting
that the acylsulfonamide moiety undergoes rapid hydrolysis to the
corresponding sulfonamide in vivo. To counteract this negative
characteristic, structurally related ortho-substituted cinnamic acid
derivatives [exemplified by compound 24 (Ki = 3 nM)], in which
the acylsulfonamide moiety was replaced by a carboxy group, were
developed as potent and selective antagonists of the EP3 receptor
[34]. Later on, yet another class of N-acylsulfonamides 25
(Ki = 0.086 nM) and 26 (Ki = 0.16 nM), developed on the basis of
L798,106 (23), represent the second class of highly potent and
selective EP3 antagonists that carry a novel structural feature: the
N-(3,4-difluorobenzene)sulfonyl moiety. Incorporation of this
moiety rendered the compounds active in vivo [35]. Additionally,
a series of 1,7-disubstituted indole scaffold-based EP3 antagonists
have been reported by DeCode Genetics, the most prominent
compound DG-041 (27) possesses an IC50 value of 4.6 nM
[36–38]. Surprisingly, DG-041 displays good plasma and metabolic
stability in spite of the presence of an acylsulfonamide group. A62 www.drugdiscoverytoday.comdifferent approach was employed by Gallant et al. who discovered
that the introduction of a propenoic acid group on a lipophilic
triaryl scaffold results in a potent EP3 antagonist. The ensuing
optimisation of this hit compound included the introduction of
an ortho-substituted lipophilic tail and the incorporation of a
constrained cyclopropan tether, ultimately resulting in compound
28, possessing a Ki value of 3 nM and an acceptable selectivity
profile over other prostanoid receptors [39].
Ono Pharmaceuticals, a dominant force in the research and
development of novel EP modulators, developed several EP3-se-
lective antagonists. Notably, ONO-AE3-240 (29) and compound
30 display extremely high binding affinity to the EP3 receptor,
with Ki values of 0.23 nM and 0.068 nM, respectively, as well as
high selectivity compared with other prostanoid receptors [40,41].
In recent years, other pharmacophores for potent EP3 antagonists
have emerged, taking the form of the 3-oxazolidinone-substituted
pyridinone 31 [42] and the aminothiadiazole 32 [43] which,
structurally speaking, differ significantly from all previously
reported EP3 antagonists. Both exhibit potent and selective EP3-
antagonistic functional activities in addition to excellent pharma-
cokinetic properties.
Despite the industry focus on EP3 antagonists, several EP3-
selective agonists have also been identified in the past decade as
potential antiulcer agents (Fig. 4b). Sulprostone (33), with an EC50
value of 0.42 nM, has been identified as one of the first potent and
selective EP3 agonists [17]. Further, Savage et al. reported the
identification of SC-46275 (34) as the most potent and highly
selective agonist of the EP3 subtype receptor discovered thus far
(EC50 = 0.04 nM) [44]. Similarly, compound MB-28767 (35) dis-
plays potency in the subnanomolar range (EC50 = 0.55 nM); how-
ever, it also displayed significant TP agonism. Researchers at Ono
Pharmaceuticals identified ONO-AE-248 (36) as one of the most
selective and potent EP3 agonists [21]. It is unique in its structure
because 11- and 15-OH groups benefit from protection in the form
of methyl ethers. Further, Shimazaki et al. reported the discovery of
a new class of selective EP3 agonists based on a 13,14-dehydro-16-
phenoxy PGE scaffold [45]. The introduction of the phenoxy
group to the v-side-chain resulted in enhanced selectivity for
EP3, as exemplified by compound 37. However, it proved to be
inactive in terms of pharmacologic activity owing to its rapid
hydrolysis in in vivo conditions. To overcome this issue, the methyl
ester of 37 was (i) replaced by a bulky ester moiety (compound 38)
or (ii) reduced to its alcohol congener (compound 39), resulting in
more-stable derivatives [45]. Although most of the reported ago-
nists are based on a prostanoid scaffold, TEI-3356 (40) is a unique
ligand in that it is a prostacyclin analogue [46]. It displays high
binding affinity – with an IC50 value of 10 pM – and high potency,
as displayed by its EC50 of 10 nM.
EP4 receptor modulators
Papers and patents describing the discovery of novel EP4 receptor
modulators represent the majority of publications describing EP
modulators. The first reported EP4 antagonist, AH-23848, proved
nonselective and has since been overtaken by more-potent and -
selective ligands. Various companies, such as Merck Frosst, GSK
and Ono Pharmaceuticals have put significant effort into
generating novel agonists and antagonists of this receptor [19].
In particular, agonists belonging to distinct structural classes
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Ki = 0.6 nM
24
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25
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Ki = 0.16 nM
IC50 = 0.40 nM
30
Ki = 0.068 nM
IC50 = 1.6 nM
Sulprostone (33)
Ki = 0.35 nM
EC50 = 0.42 nM
ONO-AE-248 (36)
Ki = 7.5 nM
37 (R = OMe, X=O); IC50  = 0.42 nM; EC50  = 0.47 nM
38 (R = pent-3-yl-oxy, X=O); IC50  = 36.2 nM; EC50  = 7.49 nM
39 (R = OH, X=H2); IC50 = 0.26 nM; EC50  = 0.12 nM
SC-46275 (34)
Ki = 29 nM
EC50 = 0.04 nM
MB-28767 (35)
Ki = 0.14 nM
EC50 = 0.55 nM
TEI-3356 (40)
Ki = 10 pM
EC50 = 10 nM
ONO-AE3-240 (29)
Ki = 0.23 nM
32
pKi = 8.9
31
pKi = 8.3
DG-041 (27)
IC50 = 4.6 nM
28
Ki = 3 nM
Kb = 5.8 nM
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FIGURE 4
Selective modulators of EP3 receptor. (a) Selective antagonists of EP3 receptor. (b) Selective agonists of EP3 receptor.
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the treatment of osteoporosis and ulcerative colitis.
The first class of EP4-selective agonists is based on the cyclo-
pentanone core (shown in Fig. 5a), exemplified by a series of 3,7-
dithiaPGE1 derivatives, including compound ONO-AE1-329 (41)
(EC50 = 3.1 nM). Introduction of thioether features into the a-
chain achieved a marked enhancement of activity and selectivity;
however, this type of compound proved to be unstable [47]. It has
been observed that these compounds undergo not only self-deg-
radation but also epimerization at position-8 (according to pros-
taglandin numbering), this being a result of rapid enolization
(Fig. 5a) [48]. To pursue the goal of developing more chemically
stable EP4 agonists, further chemical modifications were made to
the molecule. A combination of the removal of the 7-thia moiety,
the shift of sulfur to the 5-position of the a-chain and the intro-
duction of the 16-(m-methoxylmethyl)phenyl moiety as the v-
chain resulted in the discovery of compound ONO-AE1-734 (42),
optimised in terms of stability and agonist activity (EC50 = 1.6 nM)
[48]. Further optimisations resulted in the 9b-chloro derivatives,exemplified by compound 43, which were designed to prevent the
well-known self-degradation process and dehydration [48]. The
obtained compounds 41–43 also retained high subtype selectiv-
ities, but exhibited poor pharmacokinetics. Owing to the poor
pharmacokinetics of this class of compounds, researchers turned
their attention towards the development of orally available drug
candidates. The focus was shifted towards the derivatives belong-
ing to the lactam structural class encompassing pyrrolidinones,
piperidones and pyrazolidinones (Fig. 5b), because the preliminary
findings had revealed 8-aza-11-deoxyPGE1 (44), bearing the
12(R),15(S)-configuration and corresponding to the natural ste-
reochemistry of PGE2, to be a highly selective agonist of the EP4
receptor [49]. Subsequently, it became apparent that the replace-
ment of the hydroxy-cyclopentanone ring with its 2-pyrrolidi-
none counterpart was itself sufficient for achieving subtype
selectivity. More importantly, the 2-pyrrolidinone heterocycle
also imparts chemical as well as metabolic stability to the mole-
cules. The absence of the C11-OH group of the original PGE2
prevents b-elimination, but showed no detrimental effect onwww.drugdiscoverytoday.com 63
REVIEWS Drug Discovery Today  Volume 22, Number 1  January 2017
(a)
ONO-AE1-329 (41)
Ki = 9.7 nM
EC50 = 3.1 nM
ONO-AE1-734 (rivenprost; 42)
Ki = 0.7 nM
EC50 = 1.6 nM
Compound 43
Ki = 0.5 nM
EC50 = 3.2 nM
Enolization process - the cause for epimerization at C8
(b)
45
Ki = 3.1 nM
EC50 = 0.8 nM
AGN205204 (49)
Ki = 81 nM
EC50 = 0.08 nM
L902,688 (51)
Ki = 0.38 nM
EC50 = 0.6 nM
50
EC50 = 0.2 nM
46
Ki = 1.0 nM
EC50 = 0.2 nM
47
Ki = 0.94 nM
EC50 = 0.04 nM
48
Ki = 0.24 nM
8-aza-11-deoxyprostaglandin E1 (44)
Ki (EP1) > 100.000 nM
Ki (EP2) = 4.500 nM
Ki (EP3) = 3.000 nM
Ki (EP4) = 4.5 nM
EC50 = 56 nM
2-pyrrolidinone
Pyrazolidinone2-piperidone
(c)
KAG-308 (52)
Ki = 2.57 nM
EC50 = 0.15 nM
54
Ki = 6.6 nM
EC50 = 3.33 nM
55
pEC50 = 8.5
53
Ki = 0.52 nM
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FIGURE 5
Selective agonists of the EP4 receptor. (a) Derivatives based on a functionalised cyclopentane core. (b) Derivatives carrying a lactam counterpart of the
hydroxycyclopentanone core. (c) Structurally diverse EP4 agonists.
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Weither binding or agonism. In addition, the 2-pyrrolidinones are a
simplified chemical class therefore numerous derivatives were
synthesised. A structural analysis of compound 45 shows that
the a-chain of the parent compound is retained, and a biphenyl
fragment has been incorporated into the v-chain, resulting in a
high-affinity compound possessing potent agonistic activity
(Ki = 3.1 nM; EC50 = 0.8 nM) [49]. Furthermore, the interpheny-
lene analogues 46 (EC50 = 0.04 nM) and 47 (EC50 = 0.2 nM), which
incorporate aromatic acids in their a-chain, represent the most
potent and EP4-subtype-selective compounds of the series [50].
Their v-chains are terminated by either a cyclobutyl (compound
46) or an appropriately substituted biphenyl (compound 47)
moiety, which confer high subtype selectivity and retain potency.
The biphenyl subclass also enables the removal of the metaboli-
cally labile 13,14-unsaturated double bond structural feature. It is
worth noting, too, that Ono Pharmaceuticals also identified an 8-
azaprostaglandin derivative 48 as a subnanomolar agonist
(Ki = 0.24 nM) of the EP4 receptor [19]. Further insight into the
SAR was obtained with the identification of 2-piperidones, exem-
plified by compound AGN205204 (49) (EC50 = 0.08 nM), the ac-
tive metabolite of methyl ester AGN205203. The replacement of
the 2-pyrrolidinone core with its ring homologue and a minor
modification of the v-chain of compound 45 resulted in a sub-
nanomolar agonist of the EP4 receptor [51]. However, it should be
noted that minor loss in terms of affinity was observed relative to
its 2-pyrrolidinone counterpart. A similar replacement was
employed by researchers of Applied Research Systems, who
replaced the 2-pyrrolidinone heterocycle with its pyrazolidinone
counterpart, identifying compound 50 (Ki = 0.2 nM) as one of the
most potent binders to EP4 reported so far [19]. Researchers at
Merck Frosst kept the established lactam scaffold and optimised
the molecule by employing a bioisosteric replacement approach.
The tetrazole feature was introduced into the a-chain in place of
the terminal carboxylic acid functionality, with the intention of
improving bioavailability, which led to the discovery of L902,688
(51), a subnanomolar agonist of the EP4 receptor (EC50 = 0.2 nM)
[52]. The third group of EP4 agonists encompassing structurally
diverse scaffolds is presented in Fig. 5c. The structure of KAG-308
(52), a low nanomolar EP4-agonist, is somewhat unique in the
field of EP4 agonists because it is the only one based on a 7,7-
difluoroprostacyclin scaffold. Applying a similar strategy and in-
troducing the tetrazole moiety in place of the carboxylic acid
rendered the compound chemically and metabolically stable, thus
resulting in high oral bioavailability in addition to in vivo efficacy
[53]. By contrast, compounds 53, 54 and 55 are representatives of
the non-prostanoid EP4 agonists possessing (sub)nanomolar affin-
ities for EP4. The pyridone-based compound 53, which bears a
vague structural resemblance to the lactam series of EP4 agonists,
showed an affinity of 0.52 nM for EP4 [19]. Moreover, researchers
from Astellas disclosed a series of ornithin homologues, as exem-
plified by compound 54, which exerts a Ki value of 6.6 nM. Finally,
compound 55, incorporating a pyrimidinothiophene scaffold, was
identified as one of the most potent compounds (EC50 = 3.2 nM)
developed at Janssen Pharmaceuticals [19]. It is worth noting that
none of the reports describing these non-prostanoid EP4 agonists
included the selectivity data relative to other prostanoid receptors
and, as a consequence, the former cannot be regarded as EP4-
selective.By contrast, significant efforts have also been made in the
development of selective and potent EP4 antagonists (presented
in Fig. 6a) as potential drug candidates for the treatment of diverse
groups of diseases, including chronic inflammation, pain, solid
tumours and migraine. Burch et al. recently investigated a series of
quinoline acylsulfonamides designed on the basis of the known
EP4 antagonist GW-627368X and identified MF-498 (56), which
possesses subnanomolar binding potency towards EP4
(Ki = 0.74 nM; IC50 = 1.1 nM) while also exhibiting excellent se-
lectivity for EP4 relative to other prostanoid receptors [54]. To
solve the problem of metabolic instability of compound 56, more
oxidatively stable trifluoroethyl moieties were incorporated into
the molecule, and the introduction of steric hindrances, such as
the replacement of a methylene linker by a bulkier cyclopropyl
linker adjacent to the carbonyl group, resulted in MF-310 (57)
(Ki = 0.79 nM; IC50 = 3.2 nM), which showed a more favourable
pharmacokinetic profile but displayed less selectivity [54]. Unfor-
tunately, MF-310 has also been shown to undergo hydrolysis,
giving rise to the corresponding sulfonamide metabolite in in vivo
conditions. The thiophene-based MK-2894 (58) (Ki = 0.56 nM)
and nonacylsulfonamide analogue indole MF-766 (59)
(Ki = 0.23 nM) represent the second generation developed at
Merck Frosst and are highly potent and selective EP4 antagonists
in which the hydrolytically unstable acylsulfonamide moiety is
replaced by a carboxylic acid [55,56].
Pfizer’s diaryl ether CJ-42794 (60) represents yet another chem-
ical class of EP4 antagonists, showing high affinity (Ki = 3.16 nM)
as well as displaying a good selectivity profile [57]. Furthermore,
Schiffler et al. have described another interesting class of potent
and highly bioavailable EP4 antagonists, exemplified by com-
pound 61 [58]. Their structure is unique in that they are ampho-
teric and thus contain an acidic carboxylic acid functionality as
well as a basic (phenoxyethyl)piperidine functionality; this pro-
vides diverse formulation options to facilitate absorption [58]. Low
nanomolar affinity has also been reported for the naphthyl deriv-
ative ONO-AE3-208 (62) (Ki = 1.3 nM) developed by Ono Pharma-
ceuticals [59]. Researchers at Pfizer identified another potent and
highly selective EP4 antagonist, grapiprant (CJ-023,423; com-
pound 63), which showed efficacy in animal models of inflamma-
tory pain. It is based on an imidazopyridine scaffold with a
pendant sulfonylurea acidic centre [60]. Interestingly, compound
L161,982 (64) also proved to be a selective EP4 antagonist despite
its structural resemblance to the previously reported Merck EP3
antagonists [61]. Compound ER819762 (65) is atypical from a
structural point of view because it is the only reported selective
EP4 antagonist lacking an acidic centre in its structure [62]. In an
effort to discover alternative scaffolds for EP4 antagonists,
researchers at Fujisawa employed a random screening approach
so as to explore the chemical space fully. This exploration led to
the identification of diphenyloxazole 66 and a substituted Z-
ornithin derivative 67 as potent antagonists with Ki values of
0.3 nM and 0.91 nM, respectively [63]. Finally, scientists at Phar-
magene implemented an extensive virtual screening procedure
followed by several rounds of optimisation that led to the discov-
ery of a trisubstituted furan derivative PG-1531 (68); this subse-
quently proved to be a nanomolar EP4 antagonist with an
excellent selectivity profile and enhanced aqueous solubility
[64]. It has recently been demonstrated that, through thewww.drugdiscoverytoday.com 65
REVIEWS Drug Discovery Today  Volume 22, Number 1  January 2017
(a)
Prone to
oxidation
Susceptible
to hydrolysis
Trifluoroethyl groups impart
stability towards oxidation
Sterical constraints
hinder hydrolysisMF-498 (56)
Ki = 0.74 nM
IC50 = 1.1 nM
MF-310 (57)
Ki = 0.79 nM
IC50 = 3.2 nM
61
Ki = 40.6 nM
IC50 = 5.62 nM
ER819762 (65)
Ki = 70 nM
IC50 = 59 nM
Meta-substitution pattern Para-substitution pattern
68
Ki = 3 nM
pKb = 7.6
66
Ki = 0.30 nM
Compound 69
Full agonist; EC50  (EP4) = 0.20 nM
Compound 70
Full antagonist; IC50  (EP4) = 2.1 nM
(b)
67
Ki = 0.91 nM
CJ-42794 (60)
pKi = 8.2
pA2 = 8.7
L161,982 (64)
Ki = 24 nM
MF-2894 (58)
Ki = 0.56 nM
IC50 = 2.5 nM
MF-766 (59)
Ki = 0.23 nM
IC50 = 1.3 nM
CJ-023,423 (grapiprant, 63)
Ki = 13 nM
pA2 = 8.3
ONO-AE3-208 (62)
Ki = 1.3 nM
Drug Discovery Today 
FIGURE 6
Selective antagonists of the EP4 receptor and switching in the functional response as a result of minimal structural variation. (a) Selective antagonists of the EP4
receptor. (b) Switch of agonism and antagonism at the EP4 receptor.
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possible to fine-tune the intrinsic activity of the latter at the
EP4 receptor (an example is shown in Fig. 6b). For example, the
intrinsic activity (agonism vs antagonism) has been shown to
depend solely on the substitution pattern of the trifluoromethyl
substituent on the benzylic group of compounds 69 and 70 [65]. A
dramatic change of function can be achieved with minimal varia-
tion of ligand structure.
Potential therapeutic applications of selective EP
receptor modulators
Selective EP1–EP4 receptor agonists and antagonists were evaluat-
ed as drug candidates for the treatment of various diseases. We
overview the therapeutic potential of EP modulators by first pre-
senting those that are or have been evaluated in clinical studies,
and then proceed with the most promising therapeutic applica-
tions of EP modulators demonstrated in preclinical studies. The
potential therapeutic applications of EP modulators are reviewed
in Table 1.66 www.drugdiscoverytoday.comPotential therapeutic applications of EP4 modulators evaluated
in clinical trials
Use of EP4-selective agonists in the treatment of
ulcerative colitis
Ulcerative colitis manifests as impaired mucosal barrier function
and as elevated levels of proinflammatory and immunoregulatory
cytokines. The role of PGE2 in prevention of disease initiation and
progression is demonstrated in murine models of disease, indicat-
ing a pivotal role of the EP4 receptor in this process. Hence,
dextran sodium sulphate (DSS) only induced experimental colitis
in the severe form in EP4/ mice, but not in mice deficient in
other types of prostanoid receptors. The same phenotype was
reproduced in wild-type mice treated with EP4-selective antago-
nists. Induced EP4 deficiency resulted in reduced mucosal barrier
function, epithelial loss and accumulation of neutrophils and
CD4+ T cells in the colon [59]. This led to the evaluation of
EP4-selective agonists (ONO-AE1-734 and AGN205203) in wild-
type mice, resulting in prevention of DSS-induced colitis upon
their administration [51,66]. These discoveries implicated a major
Drug Discovery Today  Volume 22, Number 1  January 2017 REVIEWS
TABLE 1
Potential therapeutic applications of selective EP1–4 agonists and antagonists as drug candidates
Potential therapeutic application Drug candidate Refs
Ulcerative colitis EP4 agonists: rivenprost (ONO-4819), KAG-308
ONO-AE1-329, AGN205203
[51,53,59,66,67]
Glaucoma and intraocular hypertension EP2 agonist: taprenepag isopropyl (PF-04217329) [68,69]
Solid tumours (prostate, breast, lung) EP4 antagonists: grapiprant (CJ-023,423)
ONO-AE3-208, GW627368X, AH23848
[70–75]
Bone formation EP2 agonist: CP-533,536
EP4 agonists: ONO-4819, CP-734,432, AE1-329
[78,79]
Neurologic diseases
Alzheimer’s disease
Parkinson’s disease
EP2 agonist: butaprost
EP4 agonist: 1-hydroxy-PGE1
EP1 antagonists: SC-19220, SC-51089
[81–84]
B cell lymphoma EP4 agonist: 1-hydroxy-PGE1 [16,85–88]
Pulmonary fibrosis EP2 agonist: butaprost [89,90]
Colorectal cancer EP1 antagonist: ONO-8711
EP4 antagonist: ONO-AE2-227
[92–94]
Cardiovascular disease EP3 agonists: GR 63799X, MB-28767, ONO-AE-248, TEI-3356
EP4 agonist: EP4RAG
[95–98]
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regulating immune response, hence maintaining intestinal ho-
meostasis.
These findings laid the groundwork for use of EP4-selective
agonist rivenprost (ONO-4819) in a randomised, double-blinded
placebo-controlled Phase II clinical trial including patients with
mild-to-moderate ulcerative colitis [67]. An improvement in the
ulcerative colitis condition was observed in three out of four
patients: one patient achieved complete remission. Histological
assessments of patients suffering from ulcerative colitis further
imply the clinical benefits of rivenprost [67]. The novel EP4-
selective agonist KAG-308 is advantageous when compared with
rivenprost owing to its oral bioavailability. When tested in a
DSS-induced mouse colitis model, KAG-308 was shown to in-
hibit tumour necrosis factor (TNF)-a secretion in whole-blood
peripheral cells, whereas it also suppressed the onset of
DSS-induced colitis and promoted mucosal healing [53].
Furthermore, it showed potential in the risk prevention of
colorectal carcinogenesis. The safety of KAG-308 was evaluated
in a Phase I clinical trial (http://adisinsight.springer.com/drugs/
800039010).
Phase II clinical trial of taprenepag isopropyl, an EP2-
selective agonist, in the treatment of glaucoma and
ocular hypertension
Involvement of the EP2 receptor in intraocular pressure regulation
was confirmed in several in vivo studies wherein an EP2 receptor
agonist exhibited ocular hypotensive effects. Taprenepag isopro-
pyl (PF-04217329) is a prodrug of the active acid metabolite CP-
544326, which is a potent and selective EP2 receptor agonist [68].
Taprenepag isopropyl was evaluated in a Phase II controlled ran-
domised trial, in the form of a topical ophthalmic solution in
patients with primary open-angle glaucoma or ocular hyperten-
sion [69]. Taprenepag isopropyl monotherapy significantly re-
duced intraocular pressure and ocular hypertension and was
comparable to the conventional drug latanoprost. In addition,
the simultaneous use of taprenepag isopropyl and latanoprostdisplayed additive effects, suggesting that combination therapy
in the treatment of open glaucoma and ocular hypertension has
some benefit [69].
EP4 receptor antagonists in the treatment of solid
tumours
The effects of blocking EP4 receptor activation for the prevention
of solid tumours have been confirmed in several studies on mice
deficient in EP4 receptor, and by means of a pharmacological
blockade with EP4-selective receptor antagonists. Furthermore,
the EP4-selective antagonist grapiprant (CJ-023,423) is presently
entering Phase II clinical trials to evaluate its potential in the
treatment of advanced solid tumours, namely those of the prostate
and breast as well as non-small-cell lung cancer (NSCLC) (http://
www.clinicaltrials.gov).
The role of the EP4 receptor in prostate cancer has been studied
in detail. First, the overexpression of this receptor led to the
progression of prostate cancer in a mouse xenograft disease model
and the treatment with EP4 receptor antagonist ONO-AE3-208
suppressed castration-resistant prostate cancer progression [70].
Consistent with these findings, the EP4 receptor expression was
upregulated in prostate cancer patients [71,72].
PGE2 has an important role in lung cancer. PGE2 is abundantly
expressed in lung tissue and the inhibition of its signalling sup-
pressed tumorigenic effects in animal models of lung cancer. These
observations have further been corroborated by subsequent find-
ings that show that: (i) PGE2 promotes human NSCLC growth in
vitro and its tumorigenic effects are successfully inhibited by
pharmacologically blocking EP4 receptor with its antagonist
AH-23848 and siRNA approaches [73]; and (ii) pulmonary metas-
tasis of lung carcinoma cells injected intravenously in mice was
facilitated via the EP4 receptor. In agreement with the role of EP4
receptor in prostate and lung cancer, studies evaluating the role of
EP4 receptor in breast cancer show EP4 receptor activation medi-
ated regulation of the proliferation and invasion of inflammatory
breast cancer cells using EP4 antagonist GW-627368X and
shRNA EP4 knockdown approaches [74]. Moreover, EP4 receptorwww.drugdiscoverytoday.com 67
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murine mammary tumour cells [75].
Promising therapeutic applications of EP modulators evaluated
in preclinical studies
EP4 antagonist grapiprant shows great potential in
treating pain and inflammation
Evidently, grapiprant has been indicated in the treatment of
diverse pathologies as shown by recent studies that demonstrate
effectiveness and safety of grapiprant in the treatment of pain and
inflammation in dogs with osteoarthritis. First, grapiprant was
found to be safe in a long-term (9 months), daily oral administra-
tion in dogs [76]. Second, grapiprant proved to be effective in
alleviating pain in dogs with osteoarthritis and represents an
alternative treatment that might be better tolerated than current
therapy with non-steroid anti-inflamamtory drugs [77].
Activation of EP2 and EP4 receptors increases bone
formation
The role of PGE2 in bone remodelling is clearly demonstrated by a
local increase of endogenous PGE2 levels at the fracture site. The
effects of the EP2-selective receptor agonist CP-533,536 on local
bone augmentation, repair and healing have been evaluated in
numerous animal studies using mice, rats and dogs [78]. The effects
of EP4-selective agonists ONO-4819, CP-734,432 and ONO-AE1-
329 were evaluated in preclinical studies, which demonstrated
stimulated bone formation and increased bone mass and strength
[79]. The involvement of EP2 and EP4 receptors in this process is
evident by shared signalling pathways. EP2 and EP4 are Gs coupled,
act by activating adenylate cyclase and increase cAMP levels, and
EP4-receptor-specific signalling via Gi or EPRAP contributes to
differential outcomes [13,14]. However, signalling pathways of
EP4 and/or EP2 in osteoblasts and osteoclasts have so far not been
fully delineated. Selected insight is generated in a study utilising EP-
receptor-specific knockouts, demonstrating involvement of osteo-
blast-specific transcription factor Runx2/Cbfa1 in EP4-transduced
PGE2 signalling [79]. A study involving EP4-selective agonist ONO-
4819CD in rat models of bone repair detected an increased expres-
sion of bone morphogenetic protein (BMP)2 and receptor activator
of nuclear factor-kB ligand (RANKL) [80]. These results imply a great
potential of EP2 and EP4 agonists for therapeutic use; however, no
clinical study has taken place to date.
Protective role of EP1 and EP4 receptor signalling in
neurologic disease
The role of PGE2 and EP receptor subtypes has been identified in
several neuropathophysiological processes in various diseases of
the CNS. First, the EP2 receptor agonist butaprost and the EP4
agonist 1-hydroxy-PGE1 suppressed the neurotoxic effects of the
aggregated Ab peptides in vitro, indicating a beneficial modulatory
effect in neurodegeneration in Alzheimer’s disease [81]. The results
obtained in the conditional deletion of microglial EP4 in a trans-
genic mouse model of Alzheimer’s disease have confirmed the
protective role of anti-inflammatory EP4 signalling in the early
stages of this disease. Furthermore, EP4 receptor levels measured in
the human cortex decreased significantly with the progression
from normal to Alzheimer’s disease states, suggesting that an early
loss of the EP4 signalling system in preclinical Alzheimer’s disease
development could contribute to the subsequent progression of
the pathology [82].68 www.drugdiscoverytoday.comThe studies on rat primary dopaminergic neurons have shown
the protective role of EP1 antagonists SC-51089 and SC-19220 with
regard to the 6-hydroxydopamine-mediated toxicity in a model of
Parkinson’s disease [83,84]. This protective role has been shown in
a brain tissue model of transient focal ischemia by the pharmaco-
logical inhibition of EP1 activity as well as by genetic ablation of
the EP1 receptor [84].
EP4 receptor agonists in the treatment of B cell
lymphoma
EP4 receptor agonists exhibit a protective role in B cell lymphoma.
EP4 receptor is a negative feedback regulator of proliferation in
response to B cell receptor signalling [85–87]. EP4 signalling pre-
vented the proliferative burst of immature B cells triggered by
antigen–receptor cross-linking. In agreement with these results,
the EP4 antagonist ONO-AE3-208 blocked the effects of PGE2 after
targeting the B cell receptor in immature B cell lymphoma [85].
EP4-knockdown mice with B cell lymphoma had accelerated
tumour spread and EP4 overexpression had a protective role
against tumour progression [86]. Furthermore, the Ptger4 gene,
which codes for the EP4 receptor, has been suggested as a tumour
suppressor in mouse B cell lymphoma [86]. Antiapoptotic NF-kB-
dependent signalling pathways in B cell lymphoma were inhibited
by the EP4 receptor agonist 1-hydroxy-PGE1 [16,88]. In addition,
1-hydroxy-PGE1 increased the sensitivity of cells towards borte-
zomib- and doxorubicin-induced chemotherapeutic effects. As a
consequence, targeting the EP4 receptor could present novel
therapeutic approaches in B cell malignancies.
A protective role of EP2 activation in pulmonary
fibrosis
PGE2, abundantly expressed in lung tissue, displays suppressive
effects on fibrosis by inhibiting fibroblast proliferation, collagen
secretion and by inhibiting transforming growth factor (TGF)-b1-
induced fibroblast to myoblast differentiation [89]. A protective
role of the EP2 agonist butaprost has been observed against the
induction of idiopathic pulmonary fibrosis. This protective role is
supported by the findings that EP2 receptor/ mice showed
exaggerated fibrotic responses relative to wild-type mice in a
pulmonary-fibrosis-induced mouse model [90,91].
EP1 and EP4 receptor antagonists in the prevention of
colorectal cancer
The beneficial effects of blocking EP4 receptor signalling in colo-
rectal cancer have been confirmed in several in vivo studies as well as
by a pharmacological blockade of the EP4 receptor. For example,
the EP4/mice treated with carcinogen had reduced development
of aberrant crypt foci (precursors of colorectal tumours) relative to
wild-type mice treated with the same carcinogen [92]. The admin-
istration of the EP4 receptor antagonist ONO-AE2-227 reduced the
formation of aberrant crypt foci and intestinal polyps in a mouse
disease model [93]. Partial resistance to colon carcinogen was also
observed in mice with deletions of EP1 receptor and, in agreement
with this finding, EP1 receptor antagonist (ONO-8711) decreased
the incidence of colorectal cancer markers in vivo [94].
EP3 and EP4 receptor agonists confer cardiovascular
protection
The role of PGE2 in the pathogenesis of cardiovascular diseases and
in cardiovascular inflammation is complex. Cardioprotective
effects of EP3- and EP4-receptor-transduced signals have been
evaluated in various in vitro and in vivo models. PGE2 demonstrated
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ischemia. Thus, ischemic myocardial injury was attenuated in
transgenic mice with cardio-specific overexpression of the EP3
receptor [95]. Corroborating these findings, the structurally diverse
EP3 agonists GR-63799X, MB-28767, ONO-AE-248 and TEI-3356
reduced the myocardial infarct size in rats. The data suggest that the
therapeutic effect is mediated by PKC activation and opening of
KATP channels [96]. The EP4-selective agonist EP4RAG prevented
myocardial dysfunction after infarction and reduced infarction size
and ischemic myocardium in rat myocardial ischemia/reperfusion
injury models. EP4 receptor activation decreased the level of in-
flammatory cytokines and chemokines by inhibiting the activation
of macrophages [97]. Pharmacological activation of EP4 receptor by
EP4RAG also exhibited anti-inflammatory effects in the rat experi-
mental autoimmune myocarditis model [98]. Therefore, EP3 and
EP4 agonists represent promising cardioprotective compounds.
Concluding remarks
The EP receptors represent interesting targets to medicinal che-
mists; consequently, numerous possible indications have been
suggested for the pharmacological modulation of all EP receptor
subtypes. The literature suggests that, although the antagonists of
EP receptors have gained the interest of most of the scientific
community, some agonists have also been developed, somethingthat holds true especially in the cases of the EP2 and EP4 receptors.
Although there is an enormous amount of information regarding
the affinity, functional activity and selectivity of EP receptor
ligands, very little is known with regard to their true pharmaco-
logical value.
Novel EP receptor subtype selective agonists and antagonists
appear to be valuable drug candidates in the therapy of many
pathophysiological states, including ulcerative colitis, glaucoma,
bone healing, B cell lymphoma and Alzheimer’s disease. In addi-
tion to extensive in vitro and in vivo studies, clinical trials have been
performed to determine the clinical effect of therapeutics that
target the EP receptors. EP4 and EP2 have been particularly well
investigated in clinical trials, with Phase II clinical trials for the
treatment of ulcerative colitis (EP4) and glaucoma/ocular hyper-
tension (EP2). However, further studies are needed to evaluate the
efficacy and safety of novel drug candidates targeting EP1–4
receptors. The current state of the literature data suggests enor-
mous promise for the therapeutic potential of subtype-selective EP
receptor modulators.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.drudis.2016.08.
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